ArticleInfectious diseases and therapy2024

Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups.

Samah Hayek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.